SARS-CoV-2 and COVID-19

Dear Colleagues,

In December 2019, a previously unknown coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was isolated in Wuhan, China, from a patient with respiratory disease linked to potential contact with wild animals. The emergence of SARS-CoV-2 infection in humans has resulted in the COVID-19 pandemic, with an alarming case fatality rate, posing a threat to human health and socioeconomic activities across the world of a magnitude unprecedented since the “Spanish flu” pandemic in 1918. Multinational efforts to develop vaccines have resulted in several candidates with excellent safety and efficacy profiles in human clinical trials, and large-scale vaccination campaigns were implemented early in 2021. There are currently three Food and Drug Administration (FDA)-approved vaccines approved for emergency use against SARS-CoV-2.

In this Topical Collection about SARS-CoV-2/COVID-19, we aim to cover all the aspects related to SARS-CoV-2 infection and/or COVID-19 disease, including virus–host interactions, viral infection, transmission, pathogenesis, antivirals, vaccines, neutralizing antibodies, immunity, innate and adaptive immune responses, prophylactics, therapeutics, reverse genetics, reporter viruses, and animal models.

Our goal is for this Topical Collection of manuscripts related to SARS-CoV-2 and associated COVID-19 disease to cover the latest investigations on this important human pathogen.

Prof. Dr. Luis Martinez-Sobrido
Dr. Fernando Almazan Toral
Collection Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the Special Issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.